Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Core Viewpoint - Dianthus Therapeutics, Inc. has successfully completed a public offering of 8,470,989 shares of common stock, raising approximately $719 million to support its clinical and preclinical development activities, as well as general corporate purposes [1][2]. Group 1: Offering Details - The public offering price was set at $81.00 per share, with underwriters exercising an option to purchase an additional 1,157,407 shares [1]. - Pre-funded warrants were also offered, allowing certain investors to purchase up to 402,468 shares at a price of $80.999 per warrant, with an exercise price of $0.001 per share [1]. - The offering was conducted under a shelf registration statement that was declared effective on January 30, 2026, and included a related registration statement filed on March 10, 2026 [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to advance the company's clinical and preclinical development activities, enhance commercial readiness, and for working capital and general corporate purposes [2]. Group 3: Company Overview - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies for severe autoimmune diseases [5]. - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharmaceutical executives [5].